Perimenopause · 6 min · sourced
You're officially in menopause only after 12 full consecutive months without a period — not before. Until then, you're in late perimenopause, even if it's been 6, 9, or 11 months. This isn't just semantics: the year before your final period and the first 2–3 years after are when your bones lose density fastest and cardiovascular risk accelerates most sharply. Knowing where you stand helps you time interventions like bone density screening and hormone therapy for maximum benefit.
Menopause is diagnosed retrospectively: you've reached menopause after 12 consecutive months without menstruation, marking permanent cessation of ovarian function. You cannot confirm menopause until the full year has passed.
Until that 12-month mark, you're in late perimenopause, even if you've gone 6, 9, or 11 months without bleeding. Late perimenopause is characterized by cycles 60+ days apart or stretches of 3–11 months without menstruation. This waiting period is confusing because your hormones are already doing menopause-like things — erratic FSH spikes, unpredictable estradiol swings — but you're not technically "there" yet.
The official definition exists because it's the only reliable marker we have. But it leaves you in limbo during the very window when your bones and cardiovascular system are undergoing their most rapid changes.
FSH testing is not effective for determining menopausal status. During perimenopause, FSH fluctuates wildly day to day due to erratic ovarian activity. A high value today (say, 40 mIU/mL, well into the "menopausal range") doesn't mean it'll be high next week. Your ovaries might suddenly produce a follicle, estradiol rises, and FSH crashes back down.
Medical guidelines (NICE, ACOG) recommend diagnosing menopause based on age, menstrual history, and symptoms — not FSH testing in women 45 and over. The only reliable marker remains the retrospective one: 12 months of no bleeding.
Late perimenopause is characterized by abrupt hormonal spikes and erratic fluctuations in FSH, estradiol, and inhibin B. Your ovaries are failing unpredictably — sometimes they recruit a follicle and produce estrogen, sometimes they don't. The pituitary responds by cranking up FSH, trying to coax the ovaries into action, then dialing it back when estrogen briefly surges.
Your cycles become increasingly unpredictable: longer gaps (60+ days is typical), heavier or prolonged bleeding (10+ days), spotting between periods. Approximately 25% of perimenopausal women have heavy bleeding that persists beyond 3 months and requires medical help.
The hormonal swings don't correspond neatly to symptoms. You can have sky-high FSH and still get night sweats. You can have relatively normal estradiol and have vaginal dryness.
The most rapid bone loss occurs in the year before your final period and the first 2 years after. Lumbar spine bone density drops 1.21–1.67% per year during this window. To put that in context, premenopausal women lose bone at about 0.5% per year. You're losing bone 2–3 times faster during the transition.
About 25% of women are "fast losers" experiencing more than 7% bone mineral density loss over a 2-year period. Fast losers are at significantly higher risk of osteoporosis and fracture. We don't yet have reliable biomarkers to predict who will be a fast loser early enough to intervene.
Bone loss during perimenopause is linked to declining ovulatory activity, not just low estrogen. You can lose bone even while estrogen levels seem adequate, because your ovaries are ovulating less frequently.
No established guidelines currently address osteoporosis prevention specifically for perimenopausal women, despite the accelerated loss. If you're in late peri or early menopause, this is the window to discuss bone density screening (DEXA scan) and preventive measures with your doctor.
Sokkai tracks your cycle and symptoms together, making patterns like this visible over time. See how Sokkai works →
The menopause transition is an independent risk factor for cardiovascular disease — CVD risk accelerates during this period beyond what age alone would predict. Women develop CVD 10–15 years later than men on average, but risk increases after menopause.
The "timing hypothesis" for hormone therapy suggests cardiovascular benefit is maximized when HRT is started within 10 years of menopause onset or before age 60. Estrogens given in perimenopause or early menopause may slow atherosclerosis progression when used for symptom treatment.
The practical implication: if you're considering HRT for hot flashes or night sweats, the late peri/early menopause window is likely the most beneficial time to start from a cardiovascular standpoint. Starting HRT 15 years after menopause carries different risks and less clear benefit.
You don't need a perfect diagnosis to start protecting your bones and heart — the transition itself is the signal.
Track your menstrual history: note cycle lengths, bleeding patterns, and any gaps. If it's been 6+ months since your last period, consider this your signal to have a bone and cardiovascular risk conversation with your doctor, even though you're not technically menopausal yet.
Discuss bone density screening (DEXA scan) if you have additional risk factors (family history of osteoporosis, low body weight, smoking, prolonged periods of amenorrhea earlier in life, chronic steroid use). There's no consensus guideline for when to screen during perimenopause, but the evidence is clear that bone loss is accelerating during this window.
If you're considering HRT for symptoms, late peri/early menopause is the ideal timing window according to current evidence. The timing hypothesis suggests starting within 10 years of menopause onset or before age 60 maximizes cardiovascular benefit while minimizing risk.
Focus on modifiable lifestyle factors now:
The label "menopause" versus "late perimenopause" matters for clinical precision, but it doesn't change what your body is doing right now.
Talk to your doctor if you have bleeding after 12+ months of no periods — this requires evaluation to rule out endometrial pathology, polyps, or other causes.
Talk to your doctor if you have heavy bleeding (soaking through protection in 1–2 hours, or bleeding lasting more than 7 days) that persists beyond 3 months during perimenopause.
Talk to your doctor if you have bleeding between periods or spotting that's new or worsening.
Talk to your doctor if you're unsure whether to start bone-protective or cardiovascular interventions during late perimenopause. This is a decision-point conversation about your individual risk profile, family history, and the timing hypothesis for HRT.
Talk to your doctor if you're experiencing vasomotor symptoms (hot flashes, night sweats) severe enough to affect quality of life and wondering about HRT timing.
No specific clinical guidelines exist for preventing or treating osteoporosis in perimenopausal women, despite clear evidence of accelerated bone loss during this window. We lack consensus on when to screen during perimenopause and how aggressively to intervene.
We don't have reliable biomarkers (like anti-Müllerian hormone, AMH) that can predict which women will be "fast bone losers" early enough to intervene.
It's unclear whether cardiovascular risk reduction strategies should differ for late perimenopause versus early postmenopause, given that the transition itself is an independent risk factor. The timing hypothesis for HRT and cardiovascular benefit is supported by evidence but not definitively proven.
Sokkai tracks your cycle, symptoms and sleep in one place — so the connections that matter to your health become visible over time.
Try Sokkai free